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as rigorously and a clear understanding of the aetiology and risk of
developing either adverse event remains elusive.
Aims: The current study aims to investigate changes in cardiac
functioning in a group of patients treated with clozapine.
Method: Transthoracic echocardiograms were conducted on one
hundred and four clozapine naı¨ve patients, prior to commencing
clozapine treatment (Time 1) and were repeated after 6 to 12
months (Time 2) of treatment, as part of routine cardiac monitor-
ing. Patient psychiatric and medication history were documented,
as were full white blood count, troponin 1 and creatinine kinase
results.
Results: Preliminary analyses of the data set indicate a decrease in
left ventricular shortening, a measure of ventricular contractility,
from Time 1 (pre clozapine) to Time 2. Further analyses will be
presented.
Conclusion: While there appears to be a trend towards a worsening
of cardiac function with clozapine treatment, further investigations
need to be carried out taking into account confounding factors that
are known to be implicated in cardiac dysfunction to such as age,
BMI, smoking, medical history, familial history, amongst others.
Establishing a clearer understanding of the link between the two
will help patients and clinicians balance the risk of cardiac
problems and improved psychopathology and help to institute
cardiac monitoring guidelines for patients treated with clozapine.
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To differentiate the behavioral characteristics of schizophrenia
(SCZ) and Bipolar Disorder (BD) and generate data suitable to
validate putative animal models, we developed a human paradigm
analogous to the rodent ‘‘open field’’. The human open field is a
room in an inpatient psychiatric ward containing a desk, file
cabinet, bookcase, 10 engaging objects, and no chair. The subject is
asked to wait in the room and is monitored for 15 min. As in our
rodent Behavioral Pattern Monitor, we quantify the amount of
exploratory behavior, the sequential patterns of activity, and object
interactions. Acutely decompensated BD (N15) and SCZ (N
16) subjects were compared to healthy volunteers (N26). Studies
of mouse models included pharmacological treatments with
amphetamine or the selective dopamine transporter inhibitor
GBR12909, and genetic knockdown of the dopamine transporter.
Manic BD subjects demonstrated a unique exploratory pattern,
namely high motor activity and object exploration. SCZ subjects
failed to exhibit the expected habituation of motor activity. In mice,
selective genetic or pharmacological inhibition of the dopamine
transporter matched the mania phenotype better than the ‘‘gold
standard’’ model of mania (amphetamine). These findings validate
the human open field paradigm and identify defining characteristics
of BD that are distinct from SCZ, even during highly psychotic
states when they may otherwise be indistinguishable. This cross-
species paradigm offers an innovative approach to recording
exploratory activity in a novel environment, using procedures and
multivariate assessments that have been validated in extensive
studies of open field behavior in rodents.
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Aims: The serotonin-1A (5-HT1A) receptor has been implicated in
the pathogenesis of schizophrenia, and some antipsychotic drugs
have high affinity for this receptor. However the exact involvement
of the 5-HT1A receptor in schizophrenia and antipsychotic action
remain unclear. We previously assessed the effect of antipsychotics
on disruption of prepulse inhibition (PPI) by 5-HT1A receptor
stimulation in rats (1). PPI is a model of sensory information
processing which is deficient in schizophrenia patients. To extend
species comparison and to allow future studies in genetically-
modified animals, we aimed to further explore the involvement of
5-HT1A receptors in the action of antipsychotic drugs in mice.
Methods: Mice (n710/group) were pretreated with the typical
antipsychotics and selective dopamine D2 receptor (D2R) antago-
nists, haloperidol or raclopride (both 0.05 or 0.25 mg/kg), the
atypical antipsychotics, clozapine, olanzapine or risperidone (all 0.2
or 1 mg/kg), or the third generation antipsychotic, aripiprazole (1
or 5 mg/kg), which has partial agonist activity at both 5-HT1A and
dopamine D2 receptors. Thirty minutes later, the mice were treated
with either 1 mg/kg of the 5-HT1A receptor agonist (9)-8-hydroxy-
dipropyl-amino-tetralin (8-OH-DPAT) or saline and PPI was
assessed using automated startle boxes.
Results: Treatment with 8-OH-DPAT dose-dependently increased
PPI in Balb/c mice, but not in C57Bl/6 mice. Haloperidol,
raclopride and aripiprazole pretreatment dose-dependently blocked
the effects of 8-OH-DPAT on PPI. The atypical antipsychotics,
clozapine, olanzapine and risperidone, had only minor effects on
the action of 8-OH-DPAT on PPI.
Conclusion: These data suggest that stimulation of 5-HT1A
receptors by 8-OH-DPAT causes downstream activation of dopa-
mine D2 receptors leading to modulation of PPI. This effect
appears to be opposite in mice (increased PPI) compared to rats
(PPI disruption) which may be related to the differential activation
of pre- and postsynaptic 5-HT1A receptors, respectively (2). The
ensuing changes in PPI can be blocked directly with antipsychotic
drugs which have high affinity for 5-HT1A receptors or indirectly
by drugs which have high affinity for dopamine D2 receptors.
Further research is required to elucidate the exact mechanism of
action of 5-HT1A receptors in antipsychotic drugs, PPI, and by
extrapolation possibly in schizophrenia.
(1) Van den Buuse & Gogos, J Pharmacol Exp Ther 320, 1224
1236, 2007
(2) Gogos, Kusljic & Van den Buuse, Pharmacol Biochem Behav
81, 664672, 2006
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Aims: Although the age-dependent neurobiological processes lead-
ing to cognitive decline in the elderly remains to be fully under-
stood, there is now growing evidence to suggest that age-dependent
increases in pro-inflammatory cytokines, such as tumour necrosis
factor alpha (TNF), might play a role in such age-associated
cognitive decline. The aim of this work was to examine, using a
mouse model, the effect of a deficiency of TNF (TNF/) on
cognitive function throughout aging.
Methods: A standardized survey on cognition-like behaviour
assessing learning and retention, spatial learning/memory, and
cognitive flexibility was used to measure the cognitive-behavioural
profile of TNF knockout and wildtype mice, across three age
periods; 3, 6 and 12 months of age, respectively.
Results: All studied mice strains demonstrated successful explora-
tion and learning processes during the training phases of the tests,
which made the specific cognition like tests valid in these mice
strains. In the specific cognition-like tests, the B6.TNF/ mice
demonstrated, at 3 months of age, significantly poorer learning and
retention in the novel object test as compared to B6.WT mice. In
addition, spatial learning and learning effectiveness were signifi-
cantly poorer in B6.TNF/ mice, at 3 months of age, as
compared to B6.WT mice. While the absence of TNF was
correlated with poor cognitive functioning in early adulthood,
over time the deletion of TNF resulted in better cognitive
performance compared to B6.WT mice.
Conclusion: Low-levels of TNF under non-inflammatory immune
conditions appear essential for normal cognitive function. More-
over, the absence of TNF with age appears to protect against age-
associated cognitive decline. Collectively, these findings suggest a
possible role for TNF in the molecular and cellular mechanisms
subserving age-related changes in learning, memory and cognition.
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Background and purpose: The sex steroid hormone, estrogen, has
been proposed to be protective against schizophrenia. This study
aimed to explore whether this effect of estrogen occurs via a
modulation of the serotonin-1A (5-HT1A) receptor, which is
strongly implicated in the pathophysiology of schizophrenia.
Schizophrenia is associated with impairments of sensory processing
as measured using mismatch negativity (MMN). Further, the
loudness dependence of the auditory evoked potential (LDAEP)
has been suggested as a non-invasive electrophysiological marker of
central 5-HT function, with reduced serotonergic activity thought
to increase the LDAEP slope. This study aimed to examine the
effect of estrogen treatment on modulation of MMN and LDAEP
by the 5-HT1A receptor partial agonist, buspirone, in healthy
humans. We previously found (Gogos et al. 2006, Neuropsycho-
pharmacology), in the same subjects, that buspirone caused a
significant disruption of prepulse inhibition (a measure of sensory
gating) and pretreatment with estrogen prevented this disruption.
Approach: In a double-blind, placebo-controlled, repeated-mea-
sures design, 16 healthy female volunteers were treated with
placebo/placebo, estrogen (2 mg)/placebo, placebo/ buspirone (5
mg) and estrogen/buspirone. MMN was measured at the Fz
electrode and LDAEP was measured using dipole source localiza-
tion analysis.
Key Results: There was no significant effect of either drug treatment
on MMN amplitude or latency. However, buspirone treatment
significantly enhanced LDAEP slope in the placebo condition but
was without any effect in the estrogen condition. Further, estrogen
treatment alone resulted in a marked and significant increase of
LDAEP slope.
Conclusion: These results suggest that buspirone treatment in-
creased LDAEP by inhibiting 5-HT function and that this
inhibition was prevented by estrogen pretreatment. In addition,
estrogen was found to increase LDAEP, possibly by a direct action
on cortical pyramidal cells or by an interaction with 5-HT1A
receptors. However, neither 5-HT1A receptor activation nor estro-
gen is involved in the modulation of MMN. These results could be
important for our understanding of the mechanism by which
estrogen protects against schizophrenia.
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Background: Mismatch negativity (MMN) to tone duration devi-
ants has consistently been shown to be reduced in schizophrenia.
Here we report on MMN data obtained from 19 healthy control
subjects and 72 referrals to a specialized mental health service for
the identification of individuals at ultra-high risk (UHR) of
developing schizophrenia.
Methods: MMN was derived as subtraction waveforms of event
related potentials (ERPs) to frequent short (50 ms) or long-
duration (100ms) standard tones minus ERPs to infrequent long
or short-duration deviant tones, respectively.
Results: The largest MMN amplitudes were recorded in control
subjects compared with MMN from 12 referrals meeting criteria
for first-episode psychosis and 27 UHR referrals with significant
effects of duration type and group. Approaching significance,
reduced MMN was recorded in 5 UHR individuals making a
confirmed transition to schizophrenia one year after UHR
identification in comparison to 13 UHR individuals who did not
make such a transition.
Conclusion: Our preliminary findings suggest impaired MMN
appears to be associated with prodromal schizophrenia.
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